TWiV 967: Clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses how immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection, prevalence of SARS-CoV-2 and influenza coinfection and clinical characteristics among children and adolescents aged <18 years who were hospitalized or died with Influenza, WHO estimates of excess mortality associated with the COVID-19 pandemic, reconsideration of anti-nucleocapsid IgG antibody as a marker of SARS-CoV-2 infection post-vaccination for mild COVID-19 patients, impact of SARS-CoV-2 variants on inpatient clinical outcome, clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents, similar SARS-CoV-2 Ct value distributions in anterior nares versus nasopharyngeal samples from symptomatic children during Delta and Omicron surges, early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19, effect of Nirmatrelvir/Ritonavir vs Placebo on COVID-19─related hospitalizations and other medical visits, COVID-19 Convalescent Plasma outpatient therapy to prevent outpatient hospitalization, bacterial co-infection and empirical antibiotic therapy in patients with COVID-19, association of time to surgery after COVID-19 infection with risk of postoperative cardiovascular morbidity, demonstration of stable clusters of symptoms in long COVID, and how longitudinal analysis of t cells in COVID-19 survivors with post-acute sequelae of COVID-19 reveals associations between individual symptoms and inflammatory indexes.

Become a patron of TWiV!

• Immunological dysfunction persists for 8 months following SARS-CoV-2 infection (Nature)
• Prevalence of SARS-CoV-2 and Influenza coinfection and clinical characteristics (CDC)
• WHO estimates of excess mortality associated with the COVID-19 pandemic (Nature)
• Reconsideration of anti-nucleocapsid IgG antibody as a marker of SARS-CoV-2 infection (OFID)
• Impact of SARS-CoV-2 variants on inpatient clinical outcome (CID)
• Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection (OFID)
• Similar SARS-CoV-2 Ct value distributions in samples from symptomatic children (JPIDS)
• Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19 (CDC)
• Effect of Nirmatrelvir/Ritonavir vs placebo on COVID-19─Related hospitalizations (OFID)
• COVID-19 Convalescent Plasma outpatient therapy to prevent outpatient hospitalization (MedRxiv)
• Bacterial co-infection and empirical antibiotic therapy in patients with COVID-19 (OFID)
• Association of time to surgery after COVID-19 infection (JAMA)
• Demonstration of stable clusters of symptoms in long COVID (OFID)
• Paxlovid patient eligbiliity screening checklist (FDA)
• Longitudinal analysis of T cells in COVID-19 survivors with post-acute sequelae (OFID)
• Contribute to our MicrobeTV fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 967
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]